ASX-listed Bioxyne has upgraded its FY2025 revenue guidance from $25 million to $28 million, citing strong domestic manufacturing momentum and the upcoming commercial launch of capsules.
The news saw the firm’s share price leap 23% to 3.2 cents per share.
Bioxyne, through its Breathe Life Sciences (BLS) subsidiary, generated $12.6m in revenue in the first half of FY25, a 267% increase on the previous corresponding period, with second half sales expected to hit $15.4m, up 226%.
The company said Australian pharmaceutical manufacturing and supply was the “key driver of the growth”.
BLS is preparing for commercial batch production of two MDMA capsule formulations and said it is making “significant progress” with operations in the UK and Germany, with further market updates expected shortly.
The company cited the expansion of its Australian business alongside its imminent entry into high-growth European markets as key contributors to its revised outlook.
Guidance for FY2026 is expected in August.